Molecular signals in anti-apoptotic survival pathways

Leukemia

Volumn 15, Issue 1, 2001, Pages 21-34

  O'Gorman, D M ^a   Cotter, T G ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Apoptosis; Chemoresistance; Neoplasia; Survival pathways

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CASPASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYSTEINE PROTEINASE; FAS ANTIGEN; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; CELL KILLING; CELL SURVIVAL; CORRELATION FUNCTION; DISEASE COURSE; DRUG DETOXIFICATION; DRUG TRANSPORT; GENE CONTROL; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0035129120     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401998     Document Type: Review

References (230)

1. Death receptors: Signaling and modulation
2. Survival factors and apoptosis
3. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
4. Biochemistry of multidrug resistance mediated by the multidrug transporter
5. ABC transporters: From microorganisms to man
6. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein
7. Multidrug resistance in leukaemia
8. Signal transduction. How receptors turn Ras on
9. Ras effectors and their role in mitogenesis and oncogenesis
10. Ras signalling and apoptosis
11. Modulation of the immune response and tumor growth by activated Ras
12. Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity
13. The interaction of Ras with GTPase-activating proteins
14. Ras oncogenes in human cancer: A review
15. Pancreatic cancer: The potential clinical relevance of alterations in growth factors and their receptors
16. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene
17. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes
18. SSCP detection of N-ras promoter mutations in AML patients
19. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
20. Molecular genetics of leukaemia
21. The molecular pathophysiology of myeloid leukaemias: Ras revisited
22. Sequential acquisition of trisomy 8 and N-ras mutation in acute myeloid leukaemia demonstrated by analysis of isolated leukaemic colonies
23. Mutations and expression of the ras family genes in leukemias
24. Essential role for oncogenic Ras in tumour maintenance
25. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia
26. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells
27. The Bcl-2 protein family: Arbiters of cell survival
28. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
29. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells
30. Chronic myelogenous leukemia
31. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
32. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
33. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia
34. Transformation of hematopoietic cells by BCR/ABL requires activation of a Pl-3k/Akt-dependent pathway
35. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
36. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
37. RAS inhibitors in hematologic cancers: Biologic considerations and clinical applications
38. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression
39. Reovirus therapy of tumors with activated Ras pathway
40. Raf meets Ras: Completing the framework of a signal transduction pathway
41. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
42. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of P13-kinase survival signals
43. v-raf suppresses apoptosis and promotes growth of interleukin-3- dependent myeloid cells
44. Bcl-2 targets the protein kinase Raf-1 to mitochondria
45. Phosphorylation and regulation of Raf by Akt (protein kinase B)
46. Activation of mitorchondrial Raf-1 is involved in the antiapoptotic effects of Akt
47. Protein kinase C alpha activates RAF-1 by direct phosphorylation
48. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
49. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
50. The activation of phosphatidylinositol 3-kinase by Ras
51. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors
52. Phosphoinositide 3-kinase and the regulation of cell growth
53. Mechanisms and consequences of activation of protein kinase B/Akt
54. Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: Comparison with protein kinase B alpha
55. Apoptosis. A Bad kinase makes good
56. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: Involvement of MEK upstream of Bad phosphorylation
57. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A
58. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD
59. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines
60. PTEN: A tumour suppressor that functions as a phospholipid phosphatase
61. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines
62. Cytokine-induced protein kinase B activation and bad phosphorylation do not correlate with cell survival of hemopoietic cells
63. Multiple signals converging on NF-kappaB
64. NF-kappaB to the rescue: RELs, apoptosis and cellular transformation
65. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
66. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling
67. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
68. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes
69. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control
70. Suppression of TNF-alpha-induced apoptosis by NF-kappaB
71. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
72. Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis
73. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1
74. Nuclear factor-kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug
75. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase
76. Proteases to die for
77. Signaling defect in the activation of caspase-3 and PKCdelta in human TUR leukemia cells is associated with resistance to apoptosis
78. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
79. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer
80. Cyclic AMP signaling and gene regulation
81. Transcriptional regulation by cyclic AMP
82. The multifunctional role of the co-activator CBP in transcriptional regulation
83. CREB is a regulatory target for the protein kinase Akt/PKB
84. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB
85. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions
86. Mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response
87. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 P13 kinase to the DAF-16 transcription factor
88. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
89. Negative regulation of the forkhead transcription factor FKHR by Akt
90. Direct control of the Forkhead transcription factor AFX by protein kinase B
91. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals
92. Molecular events and mechanisms of apoptosis
93. Conversion of Bcl-2 to a Bax-like death effector by caspases
94. Regulation of cell death protease caspase-9 by phosphorylation
95. Wortmannin enhances activation of CPP32 (Caspase-3) induced by TNF or anti-Fas
96. Glycogen synthase kinase-3: Functions in oncogenesis and development
97. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
98. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression
99. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor elF-2B
100. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
101. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
102. Signal transduction by protein kinase C in mammalian cells
103. Signaling through protein kinase C
104. Regulation of protein kinase C and role in cancer biology
105. Protein kinase C isoenzymes: Regulation and function
106. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer
107. Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression
108. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression
109. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts
110. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts
111. A mutant protein kinase C that can transform fibroblasts
112. Failure of wild-type or a mutant form of protein kinase C-alpha to transform fibroblasts
113. Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells
114. Epsilon PKC acts like a marker of progressive malignancy in rat liver, but fails to enhance tumorigenesis in rat hepatoma cells in culture
115. Antisense inhibition of protein kinase C alpha reverses the transformed phenotype in human lung carcinoma cells
116. P-glycoprotein, multidrug resistance and protein kinase C
117. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha
118. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML
119. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-d-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
120. Calphostin C synergistically induces apoptosis with VP-16 in lymphoma cells which express abundant phosphorylated Bcl-2 protein
121. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis
122. Bcl-2 phosphorylation required for anti-apoptosis function
123. Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression
124. Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway
125. Direction of p21 ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2
126. P90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway
127. Protein kinase Ciota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis
128. Inhibition of apoptosis in T cells expressing human T cell leukemia virus type I Tax
129. Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase
130. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1
131. The stress-activated protein kinase pathways
132. AP-1 function and regulation
133. Activation of ternary complex factor Elk-1 by stress-activated protein kinases
134. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation
135. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death
136. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines
137. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway
138. Programmed cell death in the absence of c-Fos and c-Jun
139. Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3
140. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression
141. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death
142. Fas activates the JNK pathway in human colonic epithelial cells: Lack of a direct role in apoptosis
143. JNK activation is not required for Fas-mediated apoptosis
144. Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis
145. Different mechanisms of c-Jun NH(2)-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors
146. Ras-dependent activation of c-jun N-terminal kinase/stress activated protein kinase in response to interleukin-3 stimulation in hematopoietic BaF3 cells
147. Cellular transformation and malignancy induced by ras require c-jun
148. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
149. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat
150. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis
151. A dual function for p38 MAP kinase in hematopoietic cells: Involvement in apoptosis and cell activation
152. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells
153. Involvement of the bcl-2 gene in human follicular lymphoma
154. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs
155. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
156. Apoptotic cell death induced by c-myc is inhibited by bcl-2
157. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells
158. Bcl-xL overexpression restricts heat-induced apoptosis and influences hsp70, bcl-2, and Bax protein levels in FL5. 12 cells
159. Two CD95 (APO-1/Fas) signaling pathways
160. Expression of bcl-xL can confer a multidrug resistance phenotype
161. BCL-2 family: Regulators of cell death
162. Bcl-2 family proteins
163. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
164. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
165. Groupe d'Etude des Lymphomes de l'Adulte (GELA)
166. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia
167. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer
168. Bcl-2 oncoprotein expression in acute myeloid leukemia
169. Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia
170. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia
171. Prognostic value of bcl-2 expression in invasive breast cancer
172. Bcl-2 protein expression and long-term survival in breast cancer
173. Expression of bcl-2 and the progression of human and rodent prostatic cancers
174. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells
175. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression
176. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice
177. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis
178. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
179. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia
180. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
181. Nonionic detergents induce dimerization among members of the Bcl-2 family
182. The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli
183. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members
184. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms
185. IL-4 and insulin-like growth factor-1 inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors
186. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation
187. Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1
188. Mitochondrial control of nuclear apoptosis
189. Mitochondrial control of apoptosis
190. The role of p53 in malignancy
191. P53, cell cycle control and apoptosis: Implications for cancer
192. P53 role in DNA repair and tumorigenesis
193. Growth factor modulation of p53-mediated growth arrest versus apoptosis
194. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
195. CD95(APO-1/Fas)-mediated apoptosis: Live and let die
196. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
197. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
198. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
199. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
200. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity
201. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis
202. Activation of SAPK/JNK by camptothecin sensitises androgen-independent prostate cancer cells to Fas-induced apoptosis
203. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
204. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
205. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system
206. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
207. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
208. Expression of the Fas antigen on primary human leukemia cells
209. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs
210. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders
211. Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics
212. Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody
213. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
214. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
215. Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras
216. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B
217. PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis
218. Inhibition of the protein kinase C pathway promotes anti-CD95-induced apoptosis in Jurkat T cells
219. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells
220. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy
221. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
222. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
223. Ras genes
224. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
225. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
226. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
227. PKC412 - A protein kinase inhibitor with a broad therapeutic potential
228. Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy
229. Promise and problems of Bcl-2 antisense therapy
230. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma